CECXG

CECXG
(IUPAC) ime
	2-(1'SR,2'SR,3'SR)-2'-karboksi-3'-etilciklopropil-2-(9-ksantilmetil)glicin
Klinički podaci
Identifikatori
ATC kod	nije dodeljen
PubChem	44329042
Hemijski podaci
Formula	C22H23NO5
Mol. masa	381,421 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C22H23NO5/c1-2-12-18(20(24)25)19(12)22(23,21(26)27)11-15-13-7-3-5-9-16(13)28-17-10-6-4-8-14(15)17/h3-10,12,15,18-19H,2,11,23H2,1H3,(H,24,25)(H,26,27)/t12-,18+,19+,22+/m1/s1 ; Key: NBAKIHCDPVZWRB-UHFFFAOYSA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status

CECXG (3'-etil-LY-341,495) je istraživački lek koji deluje kao potentan i selektivan antagonist za grupu II metabotropnih glutamatnih receptora (mGluR_2/3), sa relativno dobrom selektivnošću za mGluR₃. Dok je on pet puta manje potentan nego LY-341,495 na mGluR₃, on ima 38 puta veći afinitet za mGluR₃ u odnosu na mGluR₂.^[3] To ga čini jednim od malobrojnih dostupnih liganda koji mogu da naprave razliku između dva blisko srodna receptorska podtipa.^[4]^[5]^[6]

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Collado I, Ezquerra J, Mazón A, Pedregal C, Yruretagoyena B, Kingston AE, Tomlinson R, Wright RA, Johnson BG, Schoepp DD (October 1998). „2,3'-disubstituted-2-(2'-carboxycyclopropyl)glycines as potent and selective antagonists of metabotropic glutamate receptors”. Bioorganic & Medicinal Chemistry Letters 8 (20): 2849–54. DOI:10.1016/S0960-894X(98)00510-1. PMID 9873635.
↑ Jan Egebjerg, Povl Krogsgaard-Larsen, Arne Schousboe. Glutamate and gaba receptors and transporters: structure, function and pharmacology. pp 171-173. Taylor & Francis, 2002. ISBN 0-7484-0881-9
↑ Sørensen, U. (2003). „Synthesis and Structure–Activity Relationship Studies of Novel 2-Diarylethyl Substituted (2-Carboxycycloprop-1-yl)glycines as High-Affinity Group II Metabotropic Glutamate Receptor Ligands”. Bioorganic & Medicinal Chemistry 11: 197–205. DOI:10.1016/S0968-0896(02)00387-5.
↑ Ure, J.; Baudry, M.; Perassolo, M. (2006). „Metabotropic glutamate receptors and epilepsy”. Journal of the neurological sciences 247 (1): 1–9. DOI:10.1016/j.jns.2006.03.018. PMID 16697014.

Spoljašnje veze

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[pmid9873635-3] Collado I, Ezquerra J, Mazón A, Pedregal C, Yruretagoyena B, Kingston AE, Tomlinson R, Wright RA, Johnson BG, Schoepp DD (October 1998). „2,3'-disubstituted-2-(2'-carboxycyclopropyl)glycines as potent and selective antagonists of metabotropic glutamate receptors”. Bioorganic & Medicinal Chemistry Letters 8 (20): 2849–54. DOI:10.1016/S0960-894X(98)00510-1. PMID 9873635.

[4] Jan Egebjerg, Povl Krogsgaard-Larsen, Arne Schousboe. Glutamate and gaba receptors and transporters: structure, function and pharmacology. pp 171-173. Taylor & Francis, 2002. ISBN 0-7484-0881-9

[5] Sørensen, U. (2003). „Synthesis and Structure–Activity Relationship Studies of Novel 2-Diarylethyl Substituted (2-Carboxycycloprop-1-yl)glycines as High-Affinity Group II Metabotropic Glutamate Receptor Ligands”. Bioorganic & Medicinal Chemistry 11: 197–205. DOI:10.1016/S0968-0896(02)00387-5.

[6] Ure, J.; Baudry, M.; Perassolo, M. (2006). „Metabotropic glutamate receptors and epilepsy”. Journal of the neurological sciences 247 (1): 1–9. DOI:10.1016/j.jns.2006.03.018. PMID 16697014.

[1]

[2]

[3]

[4]

[5]

[6]